Overview
Over the past 2-3 years, the Ontario Institute for Cancer Research (OICR) and Thermo Fisher Scientific (TFS) have partnered in developing genomic solutions for rapid adoption into the clinic. OICR’s collaboration with TFS resulted in the commercial launch of the Oncomine™ Comprehensive Assay (v3). The current project is focused on developing new biomarker signatures based on combined RNA and DNA sequencing with clinical utility in well-characterized patient cohorts to develop clinical diagnostic tests in cancers for pancreatic, prostate and breast cancer patients, and provide a model for adoption in other disease settings.